EUVIMEDEUVIMED entdecken
Open Access

Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno‐Oncology Combination Therapy

Daniela Santurio, Sirin Yonucu, Aiman Alam-Nazki, Birses Debir, Maciej Swat, Rachel H Rose, Inmaculada C Sorribes, Miao Zhao, Tomoko Freshwater, Piet H van der Graaf, Andrzej M Kierzek

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Daniela Santurio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK, Sheffield, UK. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Antineoplastic Combined Chemotherapy Protocols, Network Pharmacology, Computer Simulation. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IO Simulator is a Quantitative Systems Pharmacology platform implementing a mechanistic model of solid tumor–immune system interactions and the action of standard immuno‐oncology drugs. Using a tarlatamab case study, we demonstrate how IO Simulator predicts combination therapy efficacy and cytokine biomarkers, which can be statistically related to the risk of cytokine release syndrome (CRS). This allows patient stratification and identification of doses that maximize efficacy without a substantial increase in cytokine release.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsNetwork PharmacologyComputer SimulationNeoplasmsCytokinesCytokine Release SyndromeAntineoplastic Agents, ImmunologicalHumansAntibodies, Bispecific

Substanzen

Biomarkers, TumorAMG 757CytokinesAntineoplastic Agents, ImmunologicalAntibodies, Bispecific

Autor:innen und Institutionen

  • Certara UK, Sheffield, UK.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • University of Leiden, Leiden, The Netherlands.
  • School of Biosciences, University of Surrey, Guildford, UK.

Zitieren

APA

Santurio, D., Yonucu, S., Alam-Nazki, A., Debir, B., Swat, M., Rose, R. H., Sorribes, I. C., Zhao, M., Freshwater, T., van der Graaf, P. H., & Kierzek, A. M. (2026). Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno‐Oncology Combination Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70515

Vancouver

Santurio D, Yonucu S, Alam-Nazki A, Debir B, Swat M, Rose RH, et al. Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno‐Oncology Combination Therapy. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70515

BibTeX
@article{Santurio2026,
  author = {Santurio, Daniela and Yonucu, Sirin and Alam-Nazki, Aiman and Debir, Birses and Swat, Maciej and Rose, Rachel H and Sorribes, Inmaculada C and Zhao, Miao and Freshwater, Tomoko and van der Graaf, Piet H and Kierzek, Andrzej M},
  title = {Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno‐Oncology Combination Therapy},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70515}
}
Kostenlos starten →